Phase II trial of preoperative pemetrexed plus carboplatin in patients with stage IB-III nonsquamous non-small cell lung cancer (NSCLC)

John D. Hainsworth(Sarah Cannon), David R. Spigel(Sarah Cannon), David Waterhouse(Oncology Hematology Care), Victor Priego(Center for Cancer and Blood Disorders), Howard A. Burris(Deaconess Hospital), F. Anthony Greco(Campus Bio Medico University Hospital), Michael McCleod(Sarah Cannon), Kent C. Shih(Sarah Cannon), Ralph V. Boccia(Center for Cancer and Blood Disorders), R. Brian Mitchell(Virginia Cancer Institute), Fred J. Kudrik(Sarah Cannon Research Institute)
Lung Cancer
January 31, 2018
10.1016/j.lungcan.2018.01.009
Cited by 12

Related Papers

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|3.7k
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
|Nature|2014|2.4k
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
|The Lancet Oncology|2019|1.7k